Appendix 4C - quarterly

Rule 4.7B

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Name of entity

CLINUVEL PHARMACEUTICALS LIMITED

 

ABN

Quarter ended (“current quarter”)

88 089 644 119

31 DEC 2011

Consolidated statement of cash flows

 

Cash flows related to operating activities

 

Current quarter
$A’000

Year to date (6 months) $A’000

1.1

Receipts from customers

462

825

1.2

Payments for       

(a)   staff costs

(b) advertising and marketing

(c) research and development

(d) leased assets

(e) other working capital

 

(1,407)

(85)

(1,382)

(47)

(481)

 

(2,942)

(114)

(2,957)

(104)

(902)

1.3

Dividends received

1.4

Interest and other items of a similar nature received

165

398

1.5

Interest and other costs of finance paid

(7)

(17)

1.6

Income taxes paid

-

-

1.7

Other (incl GST, FBT refunds)

42

84

Net operating cash flows

 

(2,740)

 

(5,729)

 

Current quarter

$A’000

Year to date ( 6 months) $A’000

1.8

Net operating cash flows (carried forward)

 

(2,740)

 

(5,729)

 

 

Cash flows related to investing activities

 

 

1.9

Payment for acquisition of:             

(a) businesses (item 5)

(b) equity investments – financial instruments ** (see bottom of page)

(c) intellectual property

(d)   physical non-current assets

(e)   other non-current assets

-

-

-

 

-

-

-

-

-

 

-

-

1.10

Proceeds from disposal of: 

(a) businesses (item 5)

(b) equity investments – financial instruments **

(c) intellectual property

(d)   physical non-current assets

(e)   other non-current assets

 

-

215

-

-

-

 

-

2,376

-

-

-

1.11

Loans to other entities

-

-

1.12

Loans repaid by other entities

-

-

1.13

Other (provide details if material)

-

-

Net investing cash flows

 

215

 

2,376

1.14

Total operating and investing cash flows

(2,525)

(3,353)




 

Cash flows related to financing activities

1.15

Proceeds from issues of shares, options, etc.

-

-

1.16

Proceeds from sale of forfeited shares

-

-

1.17

Proceeds from borrowings

-

-

1.18

Repayment of borrowings

-

-

1.19

Dividends paid

-

-

1.20

Other (Capital Raising Costs)

-

-

Net financing cash flows

-

-

 

Net increase (decrease) in cash held

 

 

(2,525)

 

(3,353)

1.21

Cash at beginning of quarter/year to date

11,468

12,178

1.22

Exchange rate adjustments

(133)

(15)

1.23

Cash at end of quarter (see below)

8,810

8,810


** Payment for acquisition of, and proceeds from equity investments represents cash flows into financial instruments. These instruments do not meet the strict definition of a cash equivalent within AASB107 Cash Flow Statements, and are defined by the Standard to be financial assets held for trading, hence do not form part of Cash at end of quarter. As at 31st December 2011, the Cash at Bank and Investments in financial instruments total $11,752k.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Current quarter
$A'000

1.24

Aggregate amount of payments to the parties included in item 1.2

726

1.25

Aggregate amount of loans to the parties included in item 1.11

n/a

 

1.26

 

Explanation necessary for an understanding of the transactions

 

 

 

Director’s fees including payment of STI Bonus to CEO

 

Non-cash financing and investing activities

2.1

Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows



2.2

Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest



Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

Amount available

$A’000

Amount used

$A’000

3.1

Loan facilities

n/a

n/a

3.2

Credit standby arrangements

n/a

n/a

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

Current quarter

$A’000

Previous quarter

$A’000

4.1

Cash on hand and at bank

2,748

4,403

4.2

Deposits

6,000

7,000

4.3

Bank overdraft

0

0

4.4

Other (Security Deposits)

62

65

Total: cash at end of quarter (item 1.23) *

8,810

11,468

As at 31st December 2011, the Cash at Bank and Investments in long term financial instruments total $11,752k.

Acquisitions and disposals of business entities

Acquisitions

(Item 1.9(a))

Disposals

(Item 1.10(a))

5.1

Name of entity

n/a

n/a

5.2

Place of incorporation or registration

5.3

Consideration for

acquisition or disposal

5.4

Total net assets

5.5

Nature of business

Compliance statement

  1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
  2. This statement does /does not* give a true and fair view of the matters disclosed.

 

Sign here:         DIGITAL SIGNATURE ON ORIGINAL PDF            Date: 31st January 2012

(Director/Company Secretary)

Print name:      DARREN KEAMY

Notes

  1. The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
  2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flowsapplies to this report except for the paragraphs of the Standard set out below.
    • 6.2       - reconciliation of cash flows arising from operating activities to operating profit or loss
    • 9.2       - itemised disclosure relating to acquisitions
    • 9.4       - itemised disclosure relating to disposals
    • 12.1(a) - policy for classification of cash items
    • 12.3     - disclosure of restrictions on use of cash
    • 13.1     - comparative information
  3. Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

Investors' Blog Posts

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Read More

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Read More

Related Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Investor Spotlight